0 268

Cited 155 times in

The Effect of Topical Bevacizumab on Corneal Neovascularization

DC FieldValueLanguage
dc.contributor.author김상우-
dc.contributor.author김응권-
dc.contributor.author김태임-
dc.contributor.author하병진-
dc.date.accessioned2015-05-19T17:27:38Z-
dc.date.available2015-05-19T17:27:38Z-
dc.date.issued2008-
dc.identifier.issn0161-6420-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/108189-
dc.description.abstractPURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. DESIGN: Prospective, nonrandomized, masked observational case series. PARTICIPANTS: Ten eyes of 7 patients with corneal NV. METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations. RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.-
dc.description.statementOfResponsibilityopen-
dc.format.extent33~38-
dc.relation.isPartOfOPHTHALMOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdministration, Topical-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAngiogenesis Inhibitors/administration & dosage*-
dc.subject.MESHAngiogenesis Inhibitors/adverse effects-
dc.subject.MESHAntibodies, Monoclonal/administration & dosage*-
dc.subject.MESHAntibodies, Monoclonal/adverse effects-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHBevacizumab-
dc.subject.MESHCorneal Neovascularization/drug therapy*-
dc.subject.MESHCorneal Neovascularization/physiopathology-
dc.subject.MESHEpithelium, Corneal/drug effects-
dc.subject.MESHEpithelium, Corneal/pathology-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIntraocular Pressure/drug effects-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrognosis-
dc.subject.MESHProspective Studies-
dc.subject.MESHTonometry, Ocular-
dc.subject.MESHVascular Endothelial Growth Factor A/antagonists & inhibitors-
dc.subject.MESHVisual Acuity/drug effects-
dc.titleThe Effect of Topical Bevacizumab on Corneal Neovascularization-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Ophthalmology (안과학)-
dc.contributor.googleauthorSang Woo Kim-
dc.contributor.googleauthorByung Jin Ha-
dc.contributor.googleauthorEung Kweon Kim-
dc.contributor.googleauthorHungwon Tchah-
dc.contributor.googleauthorTae-im Kim-
dc.identifier.doi10.1016/j.ophtha.2008.02.013-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00525-
dc.contributor.localIdA00831-
dc.contributor.localIdA01080-
dc.contributor.localIdA04249-
dc.relation.journalcodeJ02432-
dc.identifier.eissn1549-4713-
dc.identifier.pmid18439681-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0161642008001760-
dc.subject.keywordAdministration, Topical-
dc.subject.keywordAdolescent-
dc.subject.keywordAdult-
dc.subject.keywordAngiogenesis Inhibitors/administration & dosage*-
dc.subject.keywordAngiogenesis Inhibitors/adverse effects-
dc.subject.keywordAntibodies, Monoclonal/administration & dosage*-
dc.subject.keywordAntibodies, Monoclonal/adverse effects-
dc.subject.keywordAntibodies, Monoclonal, Humanized-
dc.subject.keywordBevacizumab-
dc.subject.keywordCorneal Neovascularization/drug therapy*-
dc.subject.keywordCorneal Neovascularization/physiopathology-
dc.subject.keywordEpithelium, Corneal/drug effects-
dc.subject.keywordEpithelium, Corneal/pathology-
dc.subject.keywordFemale-
dc.subject.keywordHumans-
dc.subject.keywordIntraocular Pressure/drug effects-
dc.subject.keywordMale-
dc.subject.keywordMiddle Aged-
dc.subject.keywordPrognosis-
dc.subject.keywordProspective Studies-
dc.subject.keywordTonometry, Ocular-
dc.subject.keywordVascular Endothelial Growth Factor A/antagonists & inhibitors-
dc.subject.keywordVisual Acuity/drug effects-
dc.contributor.alternativeNameKim, Sang Woo-
dc.contributor.alternativeNameKim, Eung Kweon-
dc.contributor.alternativeNameKim, Tae Im-
dc.contributor.alternativeNameHa, Byoung Jin-
dc.contributor.affiliatedAuthorKim, Sang Woo-
dc.contributor.affiliatedAuthorKim, Eung Kweon-
dc.contributor.affiliatedAuthorKim, Tae Im-
dc.contributor.affiliatedAuthorHa, Byoung Jin-
dc.rights.accessRightsnot free-
dc.citation.volume115-
dc.citation.number6-
dc.citation.startPage33-
dc.citation.endPage38-
dc.identifier.bibliographicCitationOPHTHALMOLOGY, Vol.115(6) : 33-38, 2008-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.